Swiss healthcare innovation company Healiva has announced its partnership with Lausanne University Hospital (CHUV) for the manufacture of EpiDex®, the company’s product dedicated to aiding epidermal cell graft procedures. As an autologous product, EdpiDex® comes from the patient’s own hair follicles making it a non-invasive form of treatment.

“We are very pleased to partner with CHUV on EpiDex® production”, Healiva CEO and Cofounder Dr. Priyanka Dutta-Passecker said in a press release.

“Joining forces with a recognised centre of excellence in skin cell therapy marks a major milestone for the market launch plan for EpiDex®.”

Striving for Good Manufacturing Practices

The partnership was a strategic move for Healiva as it will allow them to access CHUV’s GMP-compliant manufacturing facilities at the CHUV Cell Production Centre (CHUV-CPC) and its expertise in the development of Advanced Therapy Medicinal Products. It also allows both Healiva and CHUV to combine their expertise to come up with the competent products in their fields.

The goal of both parties is to make EpiDex® available to patients in Switzerland.

“Healiva’s technology represents a significant opportunity to change the way we treat people with chronic wounds,” CHUV-CPC Director Dr Jean-François Brunet (PhD) said.

“We are fully committed to leveraging our experience in manufacturing technologies to support Healiva’s manufacture of EpiDex®.”